Undiluted Seraseq Fusion RNA control, duplicate libraries; bounded primary-source AMP candidate.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-10-07-1448159e6a81 · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
4 evaluations · 16 results. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: Arriba | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 13 mean Seraseq fusions identified fusions · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, Arriba row, corresponding column (JATS Tab2) |
| Configuration: Arriba | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 23.5 mean total fusions identified fusions · lower Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, Arriba row, corresponding column (JATS Tab2) |
| Configuration: Arriba | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 55.3% precision % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, Arriba row, corresponding column (JATS Tab2) |
| Configuration: Arriba | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 92.9% sensitivity % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, Arriba row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers + filter + known fusion list | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 14 mean Seraseq fusions identified fusions · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnFusion 3 callers + filter + known fusion list evaluation Consensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers + filter + known fusion list row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers + filter + known fusion list | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 14 mean total fusions identified fusions · lower Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnFusion 3 callers + filter + known fusion list evaluation Consensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers + filter + known fusion list row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers + filter + known fusion list | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 100% precision % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnFusion 3 callers + filter + known fusion list evaluation Consensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers + filter + known fusion list row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers + filter + known fusion list | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 100% sensitivity % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceEnFusion 3 callers + filter + known fusion list evaluation Consensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers + filter + known fusion list row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 14 mean Seraseq fusions identified fusions · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 15.5 mean total fusions identified fusions · lower Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 90.3% precision % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 100% sensitivity % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: STAR-Fusion | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 14 mean Seraseq fusions identified fusions · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, STAR-Fusion row, corresponding column (JATS Tab2) |
| Configuration: STAR-Fusion | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 32 mean total fusions identified fusions · lower Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, STAR-Fusion row, corresponding column (JATS Tab2) |
| Configuration: STAR-Fusion | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 43.6% precision % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, STAR-Fusion row, corresponding column (JATS Tab2) |
| Configuration: STAR-Fusion | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 100% sensitivity % · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, STAR-Fusion row, corresponding column (JATS Tab2) |
Source checking is not independent reproduction. Release 2026-10-07-1448159e6a81.
A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
7 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.accession PRJNA679580 Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.assay 500 ng input; rRNA depletion and NEBNext Ultra II directional RNA-seq; HiSeq 4000 2×151 bp, overall Seraseq mean 149 million read pairs (range 86–227 million) Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.population 14 cancer-associated synthetic fusion RNAs in GM24385 background; duplicate experiments Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.split pipeline optimization set; no independent held-out partition Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.version Not reported Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | missing or unspecified No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| description Undiluted Seraseq Fusion RNA control, duplicate libraries; bounded primary-source AMP candidate. Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| name Undiluted Seraseq Fusion RNA control, duplicate libraries Context-only references | Discovery of clinically relevant fusions in pediatric cancer No field-specific location recorded Version: Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
View linked audit checks and correction history
Release 2026-10-07-1448159e6a81 · Record review: source checked
Stable ID: amp-oncology-rna-20261007-dataset-enfusion-seraseq